« Return to News | Drug Sponsors

FDA approval spurs Vertex move to Boston waterfront

Wednesday, May 25, 2011 11:51 AM

The approval of Vertex’s Pharmaceutical’s hepatitis C treatment triggered one the biggest real estate deals in Boston’s history and is expected to spur the economic turnaround of the waterfront’s industrial area, according to a report in The Boston Globe.

Construction of two buildings totaling more than a million square feet and costing about $800 million is scheduled to begin on Fan Pier as soon as this week and be completed by 2014.

City and business leaders say the arrival of Vertex’s headquarters and about 1,500 employees from Cambridge will attract similar businesses to the area.

Fan Pier has just one building now, but plans call for an eight-building complex. Vertex said it will lease 1.1 million square feet of office and lab space over the next 15 years in two of those buildings. The company’s expansion plans were secured when the FDA approved Incivek, the first drug developed solely by the company. Analysts project the drug could see annual sales of at least $1 billion.

The deal is considered a milestone for Boston officials, who have long sought to lure a major biotechnology company from Cambridge, where many of the state’s key life sciences firms are based.

Some Vertex employees will begin moving to the waterfront this fall, into an existing building at One Marina Park Drive.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.